KPIs & Operating Metrics(New)

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Amgen (AMGN) Short-Term Debt issuances (2017)

Amgen has reported Short-Term Debt issuances over the past 2 years, most recently at $540.0 million for Q3 2017.

For Q3 2017, Short-Term Debt issuances changed N/A year-over-year to $540.0 million; the TTM value through Sep 2018 reached $540.0 million, down 46.11%, while the annual FY2011 figure was $762.0 million, N/A changed from the prior year.
Short-Term Debt issuances for Q3 2017 was $540.0 million at Amgen, up from $462.0 million in the prior quarter.
Over five years, Short-Term Debt issuances peaked at $540.0 million in Q3 2017 and troughed at $540.0 million in Q3 2017.